Haemonetics (HAE) Competitors

Align Technology (NASDAQ:ALGN) and Haemonetics (NYSE:HAE) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their media sentiment, risk, institutional ownership, valuation, profitability, earnings, analyst recommendations, dividends and community ranking.

Do insiders & institutionals believe in ALGN or HAE?

88.4% of Align Technology shares are held by institutional investors. Comparatively, 99.7% of Haemonetics shares are held by institutional investors. 0.7% of Align Technology shares are held by insiders. Comparatively, 1.8% of Haemonetics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Does the media favor ALGN or HAE?

In the previous week, Align Technology and Align Technology both had 7 articles in the media. Align Technology's average media sentiment score of 1.47 beat Haemonetics' score of -0.26 indicating that Align Technology is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Align Technology	4 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Haemonetics	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Do analysts prefer ALGN or HAE?

Align Technology presently has a consensus target price of $241.25, indicating a potential upside of 28.82%. Haemonetics has a consensus target price of $97.89, indicating a potential upside of 35.91%. Given Haemonetics' stronger consensus rating and higher probable upside, analysts plainly believe Haemonetics is more favorable than Align Technology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Align Technology	1 Sell rating(s)	4 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.67
Haemonetics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78

Which has more volatility and risk, ALGN or HAE?

Align Technology has a beta of 1.64, suggesting that its share price is 64% more volatile than the S&P 500. Comparatively, Haemonetics has a beta of 0.36, suggesting that its share price is 64% less volatile than the S&P 500.

Is ALGN or HAE more profitable?

Align Technology has a net margin of 10.54% compared to Haemonetics' net margin of 9.47%. Haemonetics' return on equity of 23.66% beat Align Technology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Align Technology	10.54%	13.84%	8.51%
Haemonetics	9.47%	23.66%	8.82%

Which has stronger earnings & valuation, ALGN or HAE?

Align Technology has higher revenue and earnings than Haemonetics. Haemonetics is trading at a lower price-to-earnings ratio than Align Technology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Align Technology	$3.98B	3.41	$421.36M	$5.49	34.11
Haemonetics	$1.36B	2.54	$117.56M	$3.31	21.76

Does the MarketBeat Community prefer ALGN or HAE?

Align Technology received 392 more outperform votes than Haemonetics when rated by MarketBeat users. Likewise, 69.73% of users gave Align Technology an outperform vote while only 61.74% of users gave Haemonetics an outperform vote.

Company	Underperform	Outperform
Align Technology	Outperform Votes 797 69.73%	Underperform Votes 346 30.27%
Haemonetics	Outperform Votes 405 61.74%	Underperform Votes 251 38.26%

Summary

Align Technology beats Haemonetics on 11 of the 17 factors compared between the two stocks.